Stevanato Q3 revenue meets expectations, but cartridge ramp evidence still outstanding

What happened

Stevanato reported Q3 FY2026 revenue of €326.1 million, up 8% year-over-year and organically, driven by continued high-value solutions demand. The result is roughly in line with the company's FY2026 guidance trajectory of €1.26–1.29 billion, though it does not yet confirm the critical cartridge capacity ramp that underpins the bull case. The press release highlights "high-value solutions" but truncates before quantifying their share or providing segment details, leaving investors without direct evidence on cartridge shipment acceleration. Management had previously guided that the Piombino Dese RTU cartridge conversion would enter commercial production by end-June 2026, implying Q3 should show the first sequential cartridge volume lift. Without explicit disclosure of cartridge volumes or margin absorption, this update is insufficient to upgrade from WAIT, as the key execution risk remains unresolved.

Implication

The 8% revenue growth confirms Stevanato is executing on its core BDS demand, but the market already prices in this steady state at 16.7x EV/EBITDA. The real upside requires evidence that new cartridge capacity is converting into revenue, as management's timeline suggested Q3 should show sequential acceleration. Until the company breaks out cartridge shipments or provides a clear margin absorption update, the stock is likely to remain range-bound between $17 and $23. The Q3 result is best read as a neutral data point: it neither derails the base case nor advances the bull case for a clean ramp. We maintain our WAIT rating with a re-assessment window of 3–6 months, looking for cartridge evidence and EBITDA margin stability above 25% before turning constructive.

Thesis delta

The thesis that Stevanato's value hinges on cartridge capacity conversion is unchanged. Q3 revenue of €326.1M (+8%) is consistent with steady demand and does not alter the bear, base, or bull scenarios materially. The critical catalyst—sequential cartridge shipment acceleration—remains unconfirmed, so the WAIT stance stands.